Bionime Corporation

Taiwan Stock Exchange 4737.TW

Bionime Corporation Revenue for the year ending December 31, 2023: USD 57.19 M

Bionime Corporation Revenue is USD 57.19 M for the year ending December 31, 2023, a -20.70% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Bionime Corporation Revenue for the year ending December 31, 2022 was USD 72.11 M, a 8.06% change year over year.
  • Bionime Corporation Revenue for the year ending December 31, 2021 was USD 66.73 M, a 12.50% change year over year.
  • Bionime Corporation Revenue for the year ending December 31, 2020 was USD 59.32 M, a -18.34% change year over year.
  • Bionime Corporation Revenue for the year ending December 31, 2019 was USD 72.64 M, a 10.67% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
Taiwan Stock Exchange: 4737.TW

Bionime Corporation

CEO Mr. Chun-Mu Huang
IPO Date Dec. 23, 2010
Location Taiwan
Headquarters No. 100, Daqing Street
Employees 1,111
Sector Health Care
Industries
Description

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.

Similar companies

4746.TW

Formosa Laboratories, Inc.

USD 2.18

1.24%

4133.TW

Abnova (Taiwan) Corporation

USD 0.93

-0.21%

4104.TW

Excelsior Medical Co., Ltd.

USD 2.57

0.00%

4106.TW

Apex Medical Corp.

USD 0.75

1.35%

1733.TW

Apex Biotechnology Corp.

USD 0.91

0.62%

StockViz Staff

January 15, 2025

Any question? Send us an email